Abstract
This paper describes a 61-year-old woman who presented with mixed connective tissue disease, which was complicated by the development of pulmonary arterial hypertension (PAH). Her condition worsened rapidly, with development of haemopthysis, tachypnoe and cardiac arrest. Doppler echocardiography showed a high systolic pulmonary arterial pressure (98 mmHg), confirmed by the right heart catheterization. Vasculopathy of the pulmonary artery vessels was detected following open lung biopsy. No pulmonary embolism was found. Because of suspicion of flare of her underlying disease, which leads to PAH, immunosuppressive treatment was started with high doses of corticosteroid and cyclophosphamide, in combination with the prostacyclin analogue, Iloprost, and low molecular weight heparin. The therapy resulted in slow recovery over 6 weeks, with control echocardiography showing normalization of the high pulmonary pressure, and the patient being capable of returning to everyday activities.
Abbreviations
- PAP:
-
Pulmonary arterial pressure
- RA:
-
Right atrial
- TR:
-
Tricuspid regurgitation
- vWFAg (<120%):
-
von Willebrand Factor antigen
- AECA (<35 U/ml):
-
Anti-endothelial cell antibodies
- aU1RNP (<5 U/ml):
-
Anti-U1RNP antibody
- TM (<3.9 ng/ml):
-
Thrombomodulin
References
Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR (1972) Mixed connective tissue disease–an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52:148–159
Alarcon-Segovia DA, Villarreal M (1987) Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC (eds) Mixed connective tissue disease and anti-nuclear antibodies. Excerpta Medica, Amsterdam, pp 33–40
Smolen JS, Steiner G (1998) Mixed connective tissue disease: to be or not to be?. Arthritis Rheum 41:768–777
Hoffman RW, Greidinger EL (2000) Mixed connective tissue disease. Curr Opin Rheumatol 12:386–390
Sharp GC (1974) Mixed connective tissue disease. Bull Rheum Dis 25:828–831
Sullivan WD, Hurst DJ, Harmon CE, Esther JH (1984) A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine 63:92–107
Eulderink F, Cats A (1981) Fatal pulmonary hypertension in mixed connective tissue disease. Z Rheumatol 40:25–29
Suzuki M, Hamada M, Sekiya M, Shigematsu Y, Go S, Hiwada K (1992) Fatal pulmonary hypertension in a patient with mixed connective tissue disease: report of an autopsy case. Intern Med 31:74–77
Ueda N, Mimura K, Sugiyama T, Kado T (1984) Mixed connective tissue disease with fatal pulmonary hypertension and a review of literature. Virchows Arch (Pathol Anat) 404:335–340
Hosoda T (1987) Review of pathology of mixed connective tissue disease. In: Kasukawa R, Sharp GC (eds) Mixed connective tissue disease and anti-nuclear antibodies. Excerpta Medica, Amsterdam, pp 281–290
Rosenberg AM, Petty RE, Cumming GR, Koechler B (1976) Pulmonary hypertension in a child with mixed connective tissue disease. J Rheumatol 6:700–704
Alpert MA, Goldberg SH, Singsen BH, Durham JB, Sharp GC, Ahmad M et al (1983) Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation 68:1182–1193
Burdt MA, Hoffman RW, Deutscher SL, Wang GS (1999) Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 42:899–909
Jones MB, Osterholm RK, Wilson RB, Martin FH, Commers JS, Bachmayer JD (1978) Fatal pulmonary hypertension and resolving immune-complex glomerulonephritis in mixed connective tissue disease. Am J Med 65:855–863
Wiener-Kronish JP, Solinger AM, Warnock ML, Churg A, Ordonez N, Golden JA (1981) Severe pulmonary involvement in mixed connective tissue disease. Am Rev Respir Dis 124:499–503
Manthorphe R, Elling H, van der Meulen JT, Freiesleben Sorensen S (1980) Two fatal cases of mixed connective tissue disease. Scand J Rheumatol 9:7–10
Prakash UBS (1988) Pulmonary manifestations in mixed connective tissue disease. Seminars Resp Med 9:318–324
Prakash UBS (1998) Respiratory complications in mixed connective tissue disease. Clin Chest Med 19:733–746
Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC (2003) Age and risk of pulmonary arterial hypertension in scleroderma. Chest 124:2098–2104
Mukerjee D, St. George D, Knight C, Davar J, Wells AU, Du Bois RM, Black CM, Coghlan JG (2004) Echocardiography and pulmonary function as creeening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 43:461–466
Ozawa T, Ninomiya Y, Honma T, Kikuchi M, Sato T, Nakano M, Arakawa M (1995) Increased serum angiotensin I-Converting enzyme activity in patients with mixed connective tissue disease and pulmonary hypertension. Scand J Rheumatol 24:38–43
Manganelli P, Salaffi F, Carotti M, Delsante G, Mozzani F (1999) Pulmonary hypertension in rheumatic diseases. Minerva Med 90:59–72
Miyata M, Suzuki K, Sakuma F, Watanabe H, Kaise S, Nishimaki T, Kasukawa R (1993) Anticardiolipin antibodies are associated with pulmonary hypertension in patients with mixed connective tissue disease or systemic lupus erythematosus. Int Arch Allergy Immunol 100:351–354
Sasaki N, Kurose A, Inoue H, Sawai T (2002) A possible role of anti-endothelial cell antibody in the sera of MCTD patients on pulmonary vascular damage relating to pulmonary hypertension. Ryumachi 42:885–894
Nishimaki T, Aotsuka S, Kondo H (1999) Immunological analysis of pulmonary hypertension in connective tissue diseases. J Rheumatol 26:2357–2362
Klings ES, Hill NS, Ieong MH, Sims RW, Korn JH, Farber HW (1999) Systemic sclerosis-associated pulmonary hypertension. Arthritis Rheum 42:2638–2645
Nicod LP (2003) Pulmonary hypertension. Swiss Med Wkly 133:103–110
Magliano M, Isenberg DA, Hillson J (2002) Pulmonary hypertension in autoimmune rheumatic diseases. Arthritis Rheum 46:1997–2009
Hoeper MM, Scharze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J (2000) Long-term treatment of primary pulmonary hypertension with aerosolised iloprost, a prostacyclin analogue. N Engl J Med 342:1866–1870
Della Bella S, Molteni M, Mocellin C, Fumagalli S, Bonara P, Scorza R (2001) Novel mode of action of Iloprost: in vitro downregulation of endothelial cell adhesion molecules. Prostaglandins 65:73–83
Bettoni L, Geri A, Airo P, Danieli E, Cavazzana I, Antonioli C, Chiesa L, Franceschini F, Grottolo A, Zambruni A, Radaeli E, Cattaneo R (2002) Systemic sclerosis therapy with Iloprost: A prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 21:244–250
Chouat A, Weitzenblum E, Higenbottam T (1996) The role of thrombosis in severe pulmonary hypertension. Eur Respir J 9:356–363
Mehta NJ, Khan IA, Mehta RN et al (2000) HIV related pulmonary hypertension. Chest 118:1133–1141
Rich S, Kaufman E, Levy PS (1992) The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76–81
Frank H, Mlczoch J, Huber K et al (1997) The effect of anticoagulant therapy in primary and anorectic drug induced pulmonary hypertension. Chest 112:714–721
Kotajuma L, Aotsuka S, Sato T (1997) Clinical significance of serum thrombomodulin levels in patients with systemic rheumatic diseases. Clin Exp Rheumatol 15:59–65
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Végh, J., Soós, G., Csipõ, I. et al. Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost. Rheumatol Int 26, 264–269 (2006). https://doi.org/10.1007/s00296-005-0616-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-005-0616-8